Compare Novo Nordisk A/S (NVO) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs TeraWulf Inc — how do they compare? Novo Nordisk A/S trades at $44.72 (market cap $200.69B), while TeraWulf Inc trades at $17.19 (market cap $8.91B). The key difference: Novo Nordisk A/S is far larger — about 22.5× TeraWulf Inc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals.
| NVO | WULF | |
|---|---|---|
Market Cap | $200.69B | $8.91B |
Sector | Health | Technology |
52-Week High | $63.98 | $28.98 |
52-Week Low | $35.29 | $10.49 |
Enterprise Value | $215.49B | $11.53B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
WULF trades at $17.86, up 8.18% today, amid a bullish technical signal despite mixed moving averages. The company reported a net loss of $661.42M in 2025 with a negative net margin of -1,179.94%, though revenue was $168.46M. Recent news highlights its pivot to AI data centers, including a Kentucky power agreement approval (GlobeNewsWire, 2026-08-24).
Analyst consensus is strongly bullish with a $35.94 price target, but high valuation ratios and persistent losses pose risks. Investment opportunity hinges on successful execution of AI infrastructure expansion, while risks include cash burn and competitive pressures in the data center space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
